You are here: Industry Insights > FASENRA

News List

First patients dosed with Fasenra in three dermatology trials europeanpharmaceuticalreview
April 26, 2021
With the addition of the new dermatology trials, Fasenra is now being evaluated in nine different indications associated with eosinophilic immune dysfunction.
AstraZeneca Pharma India gets DCGI nod for benralizumab injection, Fasenra expresspharma
December 22, 2020
It is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
FASENRA eliminated OCS in a majority of asthma patients in PONENTE Phase IIIb trial expresspharma
October 30, 2020
High-level results from the PONENTE Phase IIIb open-label trial showed FASENRA (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad range of blood eosinophil counts.
Fasenra Meets Co-Primary Endpoints americanpharmaceuticalreview
September 17, 2020
High-level results from the OSTRO Phase III trial showed AstraZeneca’s Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in nasal blockage in patients with chronic ...
AZ Fasenra shows benefit in chronic rhinosinusitis with nasal polyps pharmatimes
September 14, 2020
AstraZeneca’s Fasenra (benralizumab) significantly reduced the size of nasal polyps and cut nasal blockage in patients with chronic rhinosinusitis, raising hopes for a new treatment option for this condition.
AZ’s Fasenra study confirms robust efficacy in eosinophilic asthma pharmatimes
August 11, 2020
AstraZeneca has revealed positive results from a Phase IIIb trial of Fasenra (benralizumab) in severe eosinophilic asthma patients.
Fasenra Granted Orphan Drug Designation americanpharmaceuticalreview
September 03, 2019
AstraZeneca announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE).
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector europeanpharmaceuticalreview
July 05, 2019
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector.
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector europeanpharmaceuticalreview
July 05, 2019
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector.
AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits fiercepharma
May 21, 2019
AstraZeneca’s Fasenra has been stealing share from GlaxoSmithKline’s Nucala in severe asthma, and competition is even fiercer with Sanofi’s Dupixent approval.

Previous page 1 2 Next page